Core Viewpoint - Fosun Pharma announced a plan to spin off its subsidiary Fosun Antigen for a listing on the Hong Kong Stock Exchange, aiming to enhance financing channels and market competitiveness, despite the current downturn in the domestic vaccine industry and Fosun Antigen's poor financial performance [1][3]. Financial Performance - Fosun Antigen's revenue is projected to decline significantly from 461 million yuan in 2022 to 97.42 million yuan in 2024, with a net profit turning from a profit of 86.64 million yuan to a loss of 123.38 million yuan [3]. - The company's total assets as of December 31, 2024, are reported at 345.86 billion yuan, with a debt-to-asset ratio of 33.87% [3]. - The net cash flow from operating activities is negative at -105.29 million yuan for 2024, indicating financial strain [3]. Market Context - The domestic vaccine industry is currently facing challenges, with significant price competition among established products, leading to revenue declines for major players [6][9]. - The market for flu vaccines and rabies vaccines is particularly competitive, with price cuts from leading companies impacting overall sales [6][9]. Product Pipeline - Fosun Antigen has a limited product lineup, with four vaccines currently on the market, including rabies and flu vaccines, which are in a crowded market [5][6]. - The company is developing several vaccines, including the 13-valent and 24-valent pneumococcal conjugate vaccines, but lacks progress compared to competitors [7][10]. Competitive Landscape - The pneumococcal vaccine market is becoming increasingly competitive, with multiple players entering the space, leading to declining sales for existing products [9][12]. - Fosun Antigen's 24-valent pneumococcal vaccine is still in the early clinical trial phase, while competitors have advanced further in their development [10][12].

Core Viewpoint - Fosun Pharma is seeking new growth opportunities in the vaccine sector through the spin-off and listing of its vaccine platform, Fosun Antigen, on the Hong Kong Stock Exchange, which is seen as a strategic move to support independent development and capitalize on the revaluation of quality assets in the market [2][10]. Group 1: Spin-off and Financials - The spin-off plan announced on January 22 involves an initial issuance not exceeding 25% of the expanded total share capital of Fosun Antigen, which will remain a subsidiary of Fosun Pharma, reflecting its financial status in the consolidated financial statements [2][3]. - Fosun Antigen's projected revenues for 2022, 2023, and 2024 are 460 million yuan, 340 million yuan, and 97.42 million yuan respectively, with net profits of 86.64 million yuan, 11.35 million yuan, and a loss of 123.39 million yuan in 2024 [3][4]. Group 2: Market Potential and Competition - The global vaccine market is experiencing rapid expansion, with a size of $77 billion in 2023 and a compound annual growth rate (CAGR) of 15% from 2019 to 2023. The Chinese vaccine market (excluding COVID-19 vaccines) is expected to reach approximately 101.77 billion yuan in 2024, growing to 300 billion yuan by 2035, with an annual growth rate of about 12% [4][5]. - The Chinese vaccine market has significant growth potential, particularly in rabies and influenza vaccines, where current vaccination rates are low, indicating room for increased demand [5][6]. Group 3: Competitive Advantages and Challenges - Fosun Antigen has established a diverse range of vaccine products, including rabies and influenza vaccines, and is developing high-end products like the 13-valent pneumococcal conjugate vaccine, which is currently in Phase III clinical trials [6][7]. - The domestic vaccine market is characterized by moderate competition compared to the pharmaceutical market, with over 40 vaccine manufacturers. The focus is on collaboration to enhance market size and vaccination rates rather than engaging in cutthroat competition [5][8]. Group 4: Future Outlook - The spin-off of Fosun Antigen is part of Fosun Pharma's broader strategy to optimize asset structure and unlock the value of its subsidiaries, with previous successful spin-offs providing a framework for this move [10][11]. - The future of the vaccine market is expected to be competitive, especially in the pneumococcal vaccine sector, where established players like Pfizer dominate. The rapid development of mRNA vaccine technology poses additional challenges for traditional vaccine companies [10][11].

Core Viewpoint - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. plans to spin off its subsidiary, Fosun Antigen (Chengdu) Biopharmaceutical Co., Ltd., for a listing on the Hong Kong Stock Exchange, which is expected to maintain the company's control over the subsidiary after the split [1][6]. Group 1: Spin-off Details - The board of directors approved the spin-off proposal during a meeting held on January 22, 2026, with unanimous support from all directors [5][7]. - The spin-off is subject to various approvals, including from the company's shareholders and regulatory bodies, which introduces uncertainty regarding the timeline and feasibility of the listing [2][9]. Group 2: Financial and Operational Aspects - Fosun Antigen has reported net profits of RMB 3.731 billion, RMB 2.011 billion, and RMB 2.314 billion for the years 2022, 2023, and 2024 respectively, indicating consistent profitability over the last three years [21]. - The cumulative net profit attributable to the parent company, after excluding the subsidiary's losses, is RMB 8.076 billion, exceeding the required RMB 600 million [21][22]. Group 3: Strategic Rationale - The spin-off aims to enhance the focus on the vaccine business, which is positioned as a core area of growth amid increasing demand for innovative vaccines [40][41]. - By establishing Fosun Antigen as an independent entity, the company seeks to optimize resource allocation and improve operational efficiency, thereby enhancing competitiveness in the vaccine market [42][43]. Group 4: Market Position and Future Prospects - The spin-off is expected to unlock the valuation potential of Fosun Antigen, allowing for clearer financial analysis and potentially better market pricing [44]. - The move is aligned with the company's internationalization strategy, leveraging Hong Kong's status as a financial hub to attract global investment and partnerships [45].

该药物剂型为注射剂，规格为复溶后每支0.5mL，每1次人用剂量0.5mL，狂犬病疫苗效价应不低于 2.5IU。用法用量为每人每次用量0.5mL，于上臂三角肌肌内注射。本次试验主要目的是评价冻干人用狂 犬病疫苗（Vero细胞）以4剂和5剂基础免疫程序接种于10 - 60周岁人群的免疫持久性和2剂加强免疫的 免疫原性、安全性。 药物临床试验登记与信息公示平台数据显示，复星雅立峰（大连）生物制药有限公司的评价冻干人用狂 犬病疫苗（Vero细胞）以4剂和5剂基础免疫程序接种于10 - 60周岁人群的免疫持久性和2剂加强免疫的 免疫原性、安全性的随机、开放Ⅳ期临床试验已启动。临床试验登记号为CTR20255254，首次公示信息 日期为2026年1月12日。 目前，该实验状态为进行中（尚未招募），目标入组人数480人。 风险提示：市场有风险，投资需谨慎。本文为AI大模型基于第三方数据库自动发布，任何在本文出现 的信息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不 构成个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核 验，因此本文内容可能出现不准确 ...

本次获批的冻干人用狂犬病疫苗（Vero 细胞）是白云山生物自主研发的预防用生物制品，用于预防狂 犬病。该产品不含明胶、抗生素及防腐剂，具有中和抗体产生快、效价高、稳定性强等特点。临床试验 显示，该疫苗在10-60岁健康人群中分别采用5剂或4剂程序接种，均表现出良好的免疫原性。（智通财 经记者李科文） 12月26日，智通财经从广药集团获悉，广药集团旗下白云山生物获得国家药品监督管理局核准签发 的"冻干人用狂犬病疫苗（Vero细胞）"《药品注册证书》。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"）合并报表范围内企业广州白云山生物制 品股份有限公司（以下简称"白云山生物"）收到国家药品监督管理局核准签发关于冻干人用狂犬病疫苗 （Vero细胞）的《药品注册证书》。现将相关情况公告如下： 一、药品的基本情况 药品通用名称：冻干人用狂犬病疫苗（Vero细胞） 剂型：注射剂 证书编号：2025S03950 药品注册标准编号： 上市许可持有人：（1）名称：广州白云山生物制品股份有限公司；（2）地址：广州市经济技术开发区 连云路406号 生产企业：（1）名称：广州白云山生物制品股份有限公司；（2）地址：广州市番禺区万宝北街1号 受理号：CXSS2400079 药品批准文号：国药准字S20250069 药品批准文号有效期：至2030年12月21日 审批结论：根据《中华人民共和国药品管理法》《中华人民共和国疫苗管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证书。 规格：复溶后每瓶0.5ml。每1次人 ...

Group 1 - 德方纳米 plans annual equipment maintenance to ensure efficient and stable operation, starting January 1, 2026, for one month, with no significant impact on 2026 performance [1] - 达意隆's subsidiary Tianjin Baolong faces a significant decline in OEM orders due to strategic adjustments from core customers, leading to plans to shut down production lines [2] - 天威视讯's subsidiary plans to transfer project assets for 604.3 million yuan to a related party, constituting a related transaction [3] Group 2 - 金龙羽 intends to sign a strategic cooperation framework agreement with an investment institution to establish an industrial merger fund with a planned scale of 1.5 billion yuan [4] - 紫光国微's subsidiary plans to establish a new company with multiple partners, including a subsidiary of CATL, with a registered capital of 300 million yuan [5] - 信隆健康's major shareholder plans to reduce its stake by up to 1% through trading [6] Group 3 - 龙建股份 wins a 612 million yuan EPC contract for a project, which represents approximately 3.27% of the company's audited revenue for 2024 [7] - 复旦张江 receives acceptance for a clinical trial application for a drug aimed at visualizing malignant lesions in lung cancer patients [9] - 博实股份's major shareholder plans to reduce its stake by up to 2.93% [10] Group 4 - 百纳千成 plans to acquire 100% of Zhonglian Century's shares to expand its marketing business and digital advertising solutions [11] - 天铁科技's major shareholder is under criminal detention, but the investigation is unrelated to the company's operations [12] - 海看股份's shareholder plans to reduce its stake by up to 3.6% [13] Group 5 - 智光电气's subsidiary signs a procurement contract worth 148 million yuan for a high-voltage energy storage system [14] - 西藏矿业's attempt to transfer 100% of a subsidiary's equity has not attracted qualified buyers, leading to automatic withdrawal from the trading platform [15] - 英诺激光's major shareholder plans to reduce its stake by up to 3% [16] Group 6 - 福鞍股份's major shareholder plans to reduce its stake by up to 3% [17] - 白云山 receives a drug registration certificate for a rabies vaccine [18] - 华电科工 signs a contract worth approximately 265 million yuan for a power plant project [19] Group 7 - 康弘药业 receives a drug registration certificate for a medication used to treat schizophrenia [20] - 西菱动力's actual controller plans to reduce their stake by 2% [21] - 海希通讯's actual controller plans to reduce their stake by 0.48% [22] Group 8 - 海南机场 plans to transfer 90% of a subsidiary's equity for approximately 500 million yuan, expecting a profit of about 200 million yuan from the transaction [23] - 森远股份 signs a contract for a computing cluster integration project worth 26.78 million yuan [24] - 丽珠集团's subsidiary receives acceptance for a drug registration application for a new treatment for psoriasis [25] Group 9 - 郑州银行 plans to acquire a village bank and convert it into a branch [26] - 方正证券 announces a cash dividend distribution plan for the third quarter of 2025 [27] - 金陵体育 announces a cash dividend distribution plan for the first three quarters of 2025 [29] Group 10 - 紫金银行 announces a mid-term profit distribution plan for 2025 [30] - *ST建艺's major shareholder waives 1.4 billion yuan in debt and donates 400 million yuan to support the company [31] - 万朗磁塑's major shareholder plans to reduce their stake by up to 3% [32] Group 11 - 艾力斯's core product is included in a list of potential breakthrough therapies for lung cancer [33] - 富创精密's shareholder plans to transfer 918.63 million shares [34] - 东阳光's subsidiary plans to increase capital and introduce investors [35] Group 12 - 侨银股份 plans to acquire a 16.67% partnership in a venture capital fund [36] - 尤夫股份 receives a government subsidy of 4.04 million yuan for a technical improvement project [37] - 倍轻松 and its actual controller are under investigation for information disclosure violations [38] Group 13 - 万润新能 plans to reduce production on some lines for maintenance, expecting a reduction of 5,000 to 20,000 tons in lithium iron phosphate output [39]

广州白云山医药集团股份有限公司 证券代码：600332 证券简称：白云山公告编号：2025－094 关于广州白云山生物制品股份有限公司收到 药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"）合并报表范围内企业广州白云山生物制 品股份有限公司（以下简称"白云山生物"）收到国家药品监督管理局核准签发关于冻干人用狂犬病疫苗 （Vero细胞）的《药品注册证书》。现将相关情况公告如下： 一、药品的基本情况 药品通用名称：冻干人用狂犬病疫苗（Vero细胞） 剂型：注射剂 规格：复溶后每瓶0.5ml。每1次人用剂量为0.5ml，狂犬病疫苗效价应不低于2.5IU。 注册分类：预防用生物制品 证书编号：2025S03950 药品注册标准编号： 上市许可持有人：（1）名称：广州白云山生物制品股份有限公司；（2）地址：广州市经济技术开发区 连云路406号 生产企业：（1）名称：广州白云山生物制品股份有限公司；（2）地址：广州市番禺区万宝北街1号 受理号：CXSS240007 ...

Core Viewpoint - The National Medical Products Administration (NMPA) has approved the launch of the anti-CTLA-4 monoclonal antibody, Ipilimumab N01 injection (brand name: Daberxin), developed by Innovent Biologics, for neoadjuvant treatment in patients with resectable stage IIB-III microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer, marking it as China's first domestically approved anti-CTLA-4 monoclonal antibody and the first globally for this indication [1][5]. Group 1 - The approval is based on the results of a randomized, controlled, multi-center Phase III registration study (NeoShot-III, NCT05890742) conducted in China, which aimed to evaluate the efficacy and safety of Ipilimumab N01 in combination with Sintilimab compared to direct radical surgery [3][7]. - The primary endpoints of the study included pathological complete response (pCR) and event-free survival (EFS) [3][7]. - The interim analysis of the NeoShot-III study showed that the predefined primary endpoints were met, as assessed by the Independent Data Monitoring Committee (iDMC) [3][7]. Group 2 - As of November 28, 2024, among the first 50 patients in the trial group, 41 achieved pathological complete response after neoadjuvant treatment, resulting in a pCR rate of 82% [4][8]. - In terms of safety, the combination of Ipilimumab N01 and Sintilimab did not significantly increase additional safety risks compared to the direct surgery group [4][8]. - The Chief R&D Officer of Innovent Biologics, Dr. Zhou Hui, emphasized the significant unmet clinical need for neoadjuvant treatment in resectable MSI-H/dMMR colorectal cancer, highlighting the importance of the NeoShot-III study's interim analysis for this treatment area [4][8].

人民财讯12月25日电，白云山(600332)12月25日公告，公司合并报表范围内企业广州白云山生物制品股 份有限公司收到国家药监局核准签发关于冻干人用狂犬病疫苗（Vero细胞）的《药品注册证书》。 转自：证券时报 ...